There were no significant differences in type, age, location, symptom, menopausal status, pathological grade, axillary lymph node (ALN) status, ductal carcinoma in situ (DCIS) status or Ki-67 status between the training cohort and the validation cohort (all p > 0.05). The gene discussed is MKI67; the disease is ductal breast carcinoma in situ.